Effects of the Antioxidant Agent Tempol on Periapical Lesions in Rats with Doxorubicin-induced Cardiomyopathy

被引:29
作者
Brilhante Wolle, Carlos Frederico [1 ]
Zollmann, Luciana de Aguiar [2 ]
Etges, Adriana [4 ]
Vitalis, Graciela Schneider [5 ]
Leite, Carlos Eduardo [3 ]
Campos, Maria Martha [1 ,3 ]
机构
[1] Pontificia Univ Catolica Rio Grande do Sul, Sch Dent, BR-90619900 Porto Alegre, RS, Brazil
[2] Pontificia Univ Catolica Rio Grande do Sul, Fac Pharm, BR-90619900 Porto Alegre, RS, Brazil
[3] Pontificia Univ Catolica Rio Grande do Sul, Inst Pharmacol & Toxicol, BR-90619900 Porto Alegre, RS, Brazil
[4] Univ Fed Pelotas, Sch Dent, Dept Oral Pathol, Pelotas, Brazil
[5] Ctr Univ Franciscano, Nano Sci Coll, Santa Maria, RS, Brazil
关键词
Antioxidant therapy; cardiomyopathy; doxorubicin; periapical periodontitis; rats; PERMEABLE RADICAL SCAVENGER; (-)-EPIGALLOCATECHIN GALLATE; INTRACANAL MEDICATION; RODENT MODEL; GREEN TEA; EXPRESSION; PULP; MECHANISMS;
D O I
10.1016/j.joen.2011.11.007
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Introduction: Cardiovascular diseases have been associated with increased risk of endodontic complications. This study evaluated the effects of the antioxidant agent tempol on periapical lesions in rats with doxorubicin-induced cardiomyopathy in comparison with control animals. Methods: Forty male Wistar rats were divided into 4 groups: (1) naive rats orally treated with saline solution (10 mL/kg, during 21 days after periapical lesion induction); (2) naive rats treated with tempol (30 and 50 mg/kg, during 21 days after periapical lesion induction) by oral pathway; (3) rats with doxorubicin-induced cardiomyopathy treated with saline solution by oral route (10 mL/kg, from day 3 to day 10 after initiating treatment with doxorubicin); and (4) rats with doxorubicin-induced cardiomyopathy orally treated with tempol (30 and 50 mg/kg, from day 3 to day 10 after initiating treatment with doxorubicin). Periapical lesions were induced on the first right mandibular molar tooth. After 21 days of apical periodontitis induction, the animals were killed, and the mandibles were collected for radiographic and histologic analysis. Results: The oral administration of tempol (50 mg/kg) was able to significantly prevent the establishment of periapical lesions in either control animals or rats submitted to the model of doxorubicin-induced cardiomyopathy, according to radiographic and histologic evaluation. Nevertheless, the protective effects of tempol were virtually greater in control animals in comparison with doxorubicin-treated rats, as indicated by histologic inflammatory assessment, which might be related to the increased production of free radicals under cardiomyopathy. Conclusions: We provide novel evidence on the beneficial systemic effects of the antioxidant tempol on apical periodontitis in both control animals and rats with doxorubicin-elicited cardiomyopathy. (J Endod 2012;38:191-195)
引用
收藏
页码:191 / 195
页数:5
相关论文
共 50 条
  • [31] Unexpected doxorubicin-induced cardiomyopathy in sisters
    Arlene A. Gayle
    Kamakshi Sachidanandam
    Jill Kolesar
    H. Ian Robins
    International Cancer Conference Journal, 2012, 1 (1) : 15 - 18
  • [32] Protective effects of endothelin receptor A and B inhibitors against doxorubicin-induced cardiomyopathy
    Schwebe, Matthias
    Ameling, Sabine
    Hammer, Elke
    Monzel, Judith V.
    Bonitz, Karina
    Budde, Susanne
    Schult, Kathleen
    Oswald, Stefan
    Scheuch, Eberhard
    Grube, Markus
    Poesch, Axel
    Budde, Thomas
    Ewert, Ralf
    Schroede, Henry W. S.
    Kroemer, Heyo K.
    Bien-Moeller, Sandra
    BIOCHEMICAL PHARMACOLOGY, 2015, 94 (02) : 109 - 129
  • [33] Calsyntenin-1 Promotes Doxorubicin-induced Dilated Cardiomyopathy in Rats
    Zhu, Mingxiang
    Chen, Yibing
    Cheng, Liting
    Li, Xin
    Shen, Yanying
    Guo, Ge
    Xu, Xiang
    Li, Hanlu
    Yang, Hao
    Liu, Chunlei
    He, Kunlun
    CARDIOVASCULAR DRUGS AND THERAPY, 2024, 38 (02) : 237 - 252
  • [34] Calsyntenin-1 Promotes Doxorubicin-induced Dilated Cardiomyopathy in Rats
    Mingxiang Zhu
    Yibing Chen
    Liting Cheng
    Xin Li
    Yanying Shen
    Ge Guo
    Xiang Xu
    Hanlu Li
    Hao Yang
    Chunlei Liu
    Kunlun He
    Cardiovascular Drugs and Therapy, 2024, 38 : 237 - 252
  • [35] Concomitant Administration of Dantrolene is Sufficient to Protect Against Doxorubicin-Induced Cardiomyopathy
    Nakamura, Yoshihide
    Yamamoto, Takeshi
    Kobayashi, Shigeki
    Suetomi, Takeshi
    Uchinoumi, Hitoshi
    Oda, Tetsuro
    Sano, Motoaki
    Yano, Masafumi
    JACC: CARDIOONCOLOGY, 2025, 7 (01): : 38 - 52
  • [36] Modeling Doxorubicin-Induced Cardiomyopathy With Fibrotic Myocardial Damage in Wistar Rats
    Podyacheva, Ekaterina
    Shmakova, Tatiana
    Kushnareva, Ekaterina
    Onopchenko, Anatoliya
    Martynov, Mikhail
    Andreeva, Daria
    Toropov, Roman
    Cheburkin, Yuri
    Levchuk, Ksenia
    Goldaeva, Alexandra
    Toropova, Yana
    CARDIOLOGY RESEARCH, 2022, 13 (06) : 339 - 356
  • [37] Research progress of therapeutic drugs for doxorubicin-induced cardiomyopathy
    Chen, Ye
    Shi, Saixian
    Dai, Yan
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 156
  • [38] Unexpected doxorubicin-induced cardiomyopathy in sisters
    Gayle, Arlene A.
    Sachidanandam, Kamakshi
    Kolesar, Jill
    Robins, H. Ian
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 2012, 1 (01): : 15 - 18
  • [39] Preventive Cardioprotection of Erythropoietin Against Doxorubicin-induced Cardiomyopathy
    Xing Chen
    Yongli Chen
    Yanyong Bi
    Naikuan Fu
    Chunyan Shan
    Sili Wang
    Shahid Aslam
    Peixian Wang
    Jing Xu
    Cardiovascular Drugs and Therapy, 2007, 21 : 367 - 374
  • [40] Contribution of MLKL to the development of doxorubicin-induced cardiomyopathy and its amelioration by rapamycin
    Shimizu, Masaki
    Ohwada, Wataru
    Yano, Toshiyuki
    Kouzu, Hidemichi
    Sato, Tatsuya
    Ogawa, Toshifumi
    Osanami, Arata
    Toda, Yuki
    Nagahama, Hiroshi
    Tanno, Masaya
    Miura, Tetsuji
    Kuno, Atsushi
    Furuhashi, Masato
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2024, 156 (01) : 9 - 18